Results 181 to 190 of about 30,003 (287)

How the European Union reviews and approves ‘follow-on biologics’ or biosimilar products

, 2009
Nicolas Rossignol
openalex   +2 more sources

Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? [PDF]

, 2012
J. B. Warren
openalex   +1 more source

The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes

Diabetes, Obesity and Metabolism, Volume 27, Issue S5, Page 24-35, July 2025.
Abstract The health economic value of insulin is usually expressed within a cost‐effectiveness framework providing an estimated incremental cost per quality‐adjusted life year (QALY) gained. Insulin clinical trials adopt a treat‐to‐target design in which both intervention and control arms aim to achieve similar levels of glycaemic control thereby ...
Phil McEwan, Marc Evans
wiley   +1 more source

Biosimilars and the extrapolation of indications for inflammatory conditions

Biologics: Targets & Therapy, 2017
John RP Tesser,1 Daniel E Furst,2 Ira Jacobs3 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2UCLA Health, Los Angeles, CA, 3Pfizer Inc, New York, NY, USA Abstract: Extrapolation is the approval of a biosimilar for use in an indication ...
Tesser JRP, Furst DE, Jacobs I
doaj  

The role of biosimilars in the treatment of rheumatic diseases [PDF]

, 2012
Thomas Dörner, Vibeke Strand, Gilberto Castañeda‐Hernández, Gianfranco Ferraccioli, John D. Isaacs, Tore K Kvien, E. Martín‐Mola, Thomas Mittendorf, Josef S Smolen, Gerd R Burmester   +9 more
openalex   +1 more source

Accelerating innovation and ensuring the thoughtful withdrawal of lifeline medicines for people living with diabetes in Asia

Journal of Diabetes Investigation, Volume 16, Issue 7, Page 1147-1150, July 2025.
Coordinated regional action is urgently needed to safeguard insulin access in Asia amid global product realignment. This editorial emphasizes the ethical imperative and policy frameworks required to balance innovation with equitable, uninterrupted diabetes care.
Yutaka Seino, Daisuke Yabe, Sung Hee Choi, Chih‐Cheng Hsu, Chien‐Ning Huang, Altaisaikhan Khasag, Kathryn Tan, Kohjiro Ueki, Yuichiro Yamada, Zhanay A Akanov, Takashi Kadowaki   +10 more
wiley   +1 more source

Biosimilars: Company Strategies to Capture Value from the Biologics Market [PDF]

, 2012
Bruno Calo-Fernández, J. L. Martínez-Hurtado   +1 more
openalex   +1 more source

Presently available biosimilars in hematology-oncology: G-CSF [PDF]

, 2012
Pere Gascón
openalex   +1 more source

Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study

Acta Medica Indonesiana, 2019
Background: treatment of erythropoietin (EPO) is essential in chronic kidney disease (CKD) patients to maintain optimal hemoglobin (Hb) level. Renogen is a biosimilar epoetin-α, and Eprex is the originator epoetin-α.
Ni Made Hustrini, Parlindungan Siregar, Arini Setiawati, Pringgodigdo Nugroho   +3 more
doaj  

Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market? [PDF]

, 2012
Lisa S. Rotenstein, Nina A. Ran, Joseph P. Shivers, Mark Yarchoan, Kelly L. Close   +4 more
openalex   +1 more source